MedTrace Logo

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

NCT06510309 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-03-13

No results posted yet for this study

Summary

The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL).

The names of the study drugs involved in this study are:

* Venetoclax (a type of inhibitor)
* Rituximab (a type of antibody)

Conditions

Interventions

DRUG

Venetoclax

B-cell lymphoma inhibitor, tablets taken orally per protocol.

DRUG

Rituximab

Anti-CD20 monoclonal antibody, 10mL or 50 mL single-use vials, via intravenous (into the vein) infusion per protocol.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Gottfried von Keudell, MD PhD

    lead OTHER

Principal Investigators

  • Gottfried von Keudell, MD, PhD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-11
Primary Completion
2028-10-31
Completion
2031-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06510309 on ClinicalTrials.gov